Attribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours (NETs) Among Patients, Clinicians and Nurses in Australia.

ABSTRACT:

Background

Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in well-differentiated low and intermediate grade 1-2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs). As a long-term treatment option for NETs, treatment preferences should be taken into consideration. The objective of this study is to evaluate the relative importance of different LA SSA treatment features among patients with NETs, clinicians and nurses in Australia.

Methods

A discrete choice experiment (DCE) method was used to analyse treatment preferences for NETs, embedded in an online survey. Participants could choose between three hypothetical treatment options: 'deep subcutaneous injectable treatment', 'deep intramuscular injectable treatment', 'oral treatment';

SUBMITTER: Fifer SJ 

PROVIDER: S-EPMC12606003 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature